Outlook TherapeuticsOTLK 
-1.82%24h
Outlook Therapeutics (OTLK) Stock Overview
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
OTLK Stock Information
Outlook Therapeutics (OTLK) Price Chart
Outlook Therapeutics Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $5.93 | N/A |
| Market Cap | $1.48B | N/A |
| Shares Outstanding | 250.18M | 17.96% |
| Employees | 24.00 | N/A |
| Shareholder Equity | -14.44M | -265.26% |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | -24.71 | N/A |
| P/B Ratio | -102.75 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | 4.0853 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $0 | N/A |
| Earnings | -$58.98M | N/A |
| EPS | -0.24 | N/A |
| Earnings Yield | -0.0405 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $32.30M | N/A |
| Total Debt | $35.56M | N/A |
| Cash on Hand | $23.39M | N/A |
| Debt to Equity | -3.2372 | -242.90% |
| Cash to Debt | 0.6579 | -58.56% |
| Current Ratio | 0.6629 | -52.48% |
